Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of Redirected Autologous T Cells With a GPC3-targeted Chimeric Antigen Receptor in Patients With Refractory Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

Clinical Study of Redirected Autologous T Cells With a GPC3-targeted Chimeric Antigen Receptor in Patients With Refractory Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GPC3-CAR-T (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Liver cancer
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 05 May 2020 Results (n=13) of pooled analysis of two studies (NCT02395250 & NCT03146234) assessing feasibility and safety of CAR-GPC3 T-cell therapy in adult Chinese patients with advanced, published in the Clinical Cancer Research.
    • 22 Aug 2019 Status changed from recruiting to completed.
    • 23 Jun 2017 According to a CARsgen Therapeutics media release, data from this trial presented at the 2017 BIO International Convention 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top